METHOXISAL-C 1/4 16.2 MG
CODEINE PHOSPHATE : 16.2 MG METHOCARBAMOL : 400 MG ACETYLSALICYLIC ACID : 325 MG · DIN 01966367 · TEVA CANADA LIMITED
Health Canada status: CANCELLED POST MARKET
What is METHOXISAL-C 1/4?
METHOXISAL-C 1/4 16.2 MG contains CODEINE PHOSPHATE : 16.2 MG METHOCARBAMOL : 400 MG ACETYLSALICYLIC ACID : 325 MG. It is listed in the Health Canada Drug Product Database under DIN 01966367, held by TEVA CANADA LIMITED, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 12-Nov-2018. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 01966367 |
|---|---|
| Brand name | METHOXISAL-C 1/4 |
| Generic / active ingredient | CODEINE PHOSPHATE : 16.2 MG METHOCARBAMOL : 400 MG ACETYLSALICYLIC ACID : 325 MG |
| Manufacturer | TEVA CANADA LIMITED |
| Strength | 16.2 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | NARCOTICS (CDSA I) |
| ATC code | N02AA59 CODEINE, COMBINATIONS EXCL. PSYCHOLEPTICS |
| AHFS class | 28:08.08 ; 12:20.04 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 12-Nov-2018 |
| Original market date | 1998-05-19 00:00:00 |
How is this product identified?
Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.
| DIN (8-digit, as used in Nexara ordering) | 01966367 |
|---|---|
| DIN (unpadded, as printed on some documents) | 1966367 |
| Brand name | METHOXISAL-C 1/4 |
| Active ingredient / INN | CODEINE PHOSPHATE : 16.2 MG METHOCARBAMOL : 400 MG ACETYLSALICYLIC ACID : 325 MG |
| ATC code | N02AA59 |
| ATC anatomical main group | N — Nervous system |
| ATC therapeutic subgroup | N02 |
| AHFS class | 28:08.08 ; 12:20.04 |
| Health Canada schedule | NARCOTICS (CDSA I) |
| Biosimilar biologic | No |
| Market authorization holder | TEVA CANADA LIMITED |
Which pack is which?
| Strength on the label | 16.2 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
What can be used instead?
Other Canadian products sharing ATC code N02AA59 CODEINE, COMBINATIONS EXCL. PSYCHOLEPTICS. 1 of 25 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ROBAXACET-8 | 400 MG | TABLET | HALEON CANADA ULC | MARKETED | DIN 01934767 |
| AXACET-C1/8 | 8 MG | TABLET | TECHNILAB PHARMA INC. | CANCELLED (UNRETURNED ANNUAL) | DIN 02237996 |
| AXISAL-C1/8 | 8 MG | TABLET | TECHNILAB PHARMA INC. | CANCELLED (UNRETURNED ANNUAL) | DIN 02237997 |
| METHOXACET-C 1/8 | 8 MG | TABLET | TEVA CANADA LIMITED | CANCELLED POST MARKET | DIN 02236872 |
| METHOXISAL-C 1/2 | 32.4 MG | TABLET | TEVA CANADA LIMITED | CANCELLED POST MARKET | DIN 01966375 |
| METHOXISAL-C 1/8 | 8 MG | TABLET | TEVA CANADA LIMITED | CANCELLED POST MARKET | DIN 01941895 |
| MUSCLE & BACK PAIN RELIEF - 8 | 325 MG | TABLET | VITA HEALTH PRODUCTS INC | CANCELLED POST MARKET | DIN 02242180 |
| MUSCLE & BACK PAIN RELIEF-8 | 400 MG | TABLET | PHARMASCIENCE INC | CANCELLED POST MARKET | DIN 02243047 |
| MUSCLE AND BACK PAIN RELIEF CAPLETS | 8 MG | TABLET | JAMP PHARMA CORPORATION | APPROVED | DIN 02258978 |
| MUSCLE AND BACK PAIN RELIEF-8 | 400 MG | TABLET | TEVA CANADA LIMITED | CANCELLED POST MARKET | DIN 02248977 |
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.